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Abstract 
APO866 is an inhibitor of NAD biosynthesis which exhibits potent antitumor properties in 
various malignancies. Recently, it has been shown that APO866 induces apoptotic and 
autophagy mediated cell death in human hematological cancer cells. However, the 
involvement of autophagy in APO866-induced cell death remains unclear. Here, we report 
studies on the molecular mechanisms underlying APO866-induced cell death with emphasis 
on autophagy. Treatment of hematological malignant cells with APO866 increases caspase 
activation as revealed by cleavage of caspase-3 and also enhances autophagic activities which 
are evidenced by an increase in autophagosome formation (LC3-II expression and LC3 
punctate labeling). APO866-mediated autophagy selectively depletes catalase, a reactive 
oxygen species (ROS) scavenger, leading to ROS production and cell death. Inhibition of 
autophagy with lentivirally mediated transduction of shRNAs targeting the autophagic 
proteins ATG5, ATG7 and Beclin1 (ATG6) clearly abrogates APO866-induced cell death in 
hematopoietic malignant cells. Altogether, our results provide direct evidence that autophagy 
is essential for the cytotoxicity-mediated by APO866 on human leukemia cells, and open new 
way to enhancing the antitumor activities of APO866 by modulation of autophagic 
machinery. 
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Introduction 
Inhibition of tumor growth by manipulating the cellular energy stores through nicotinamide 
and adenosine triphosphate (ATP) was theorized to be important mediators of the apoptotic 
biochemical cascade [1]. In this respect, several recent studies [2-5] reported the antitumor 
activities of a novel agent, APO866, that inhibits specifically nicotinamide 
phosphoribosyltransferase (NAMPT), a rate-limiting enzyme in the mammalian salvaging 
pathway for the synthesis of nicotinamide adenine dinucleotide (NAD) [6, 7]. NAD plays a 
crucial role as a cofactor/substrate in numerous biochemical and biological processes, 
including those catalyzed by poly(ADP-ribose) polymerase 1 (PARP1), sirtuins, and ADP-
ribosyl cyclase [1-6]. NAMPT activity is essential for replenishing cellular NAD levels in 
mammalian cells, and the demand for NAD is tremendously increased in cancer cells 
compared with normal cells mainly due to genomic instability and persistent PARP1-
dependent DNA repair [8, 9]. Thus, NAMPT has been shown to be an attractive therapeutic 
target for the development of new anticancer agents. Mechanistic studies revealed that 
APO866-mediated cell death involves NAD and ATP depletion, the loss of mitochondria 
membrane potential, caspase activation and autophagy-associated cell death [2, 3, 10, 11]. 
However, direct evidences of implication of autophagy in APO866-induced cell death are 
scarce.  
 Macroautophagy (hereafter called autophagy) is a physiological and essential self-digestion 
process for degradation of long-lived proteins and organelles and recycling of intracellular 
components [13]. During autophagy portions of cytosol containing the cellular material that 
need to be degraded are engulfed in multi-membrane vesicles termed autophagosomes. The 
mature autophagosomes fuses then with a lysosome, which contains the acidic hydrolases 
necessary for autophagic degradation creating a large compartment named autolysosomes 
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[12]. Autophagic degradation is important for basic homeostasis and for generation of amino 
acids and fatty acids used during protein synthesis and energy production. Autophagy is then 
often involved in cell survival when activated under starvation conditions [12-15]. However 
in other stress conditions enhanced autophagy could be implicated in promoting cell death as 
a mediator of apoptosis or necrosis or as an independent mechanism of death termed 
autophagic –associated cell death or programmed cell death type II (PCD II) [13]. To provide 
evidence of a pro-death role of autophagy, the common strategy has been to show that its 
inhibition protects or at least delays the cell death [14]. Several recent studies, have shown 
that certain forms of cell death are prevented in either the presence of pharmacological 
autophagy inhibitors or reduced autophagy related genes (ATG) expression, a group of 
autophagy regulatory genes conserved from yeast to humans [15], indicating that autophagy 
participates directly in the death process. Billington et al [10] and Cea et al, 2012 [16] 
reported that NAD synthesis inhibition induced autophagy in neuroblastoma and multiple 
myeloma cells, respectively. In addition, we previously showed that APO866-induced cell 
death in hematological malignant cells was attenuated in presence of pharmacological 
autophagy inhibitors [3]. These findings suggest that autophagy might be involved in 
APO866-induced cell death. However due to the incomplete specificity of these inhibitors 
definitive conclusion could not be made. To clarify the relationship between autophagy and 
APO866-induced cell death and to identify molecular mechanisms by which autophagy can 
be involved in leukemia cells death, we used in the present study specific inhibition of 
autophagy by lentiviral mediated transduction of shRNAs targeting three important Atg 
proteins: Atg7, Atg5 and Beclin1. We now provide clear evidence that treatment of human 
leukemia/lymphoma cells with APO866 increases a Beclin1-independent autophagy involved 
in catalase degradation, one of the main cellular antioxidants. Consequent depletion of 
catalase results in increased ROS production and cell death. Inhibition of autophagy by 
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downregulation of Atg5 and Atg7 or extracellular addition of catalase abrogates APO866-
induced cell death. 
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Materials and Methods 
Reagents and antibodies 
Clinical grade APO866 and Fas agonist (MegaFasL) were provided by TopoTarget 
(Lausanne, Switzerland). CaspGlow rhodamine active caspase-3, -8, and -9 staining kit was 
purchased from BioVision Inc (Milpitas, CA). The 5,5’,6,6’–tetrachloro-1,1’,3,3’–
tetraethylbenzimididazolyl-carbocyanine iodide (JC-1) was purchased from Calbiochem (San 
Diego, CA). 2',7'-Dichlorofluorescein diacetate (DCFH-DA), chloroquine, and catalase were 
purchased from Sigma-Aldrich (St Louis, MO). Dihydroethidium and MitoSOX Red 
mitochondrial superoxide indicator were obtained from Life Technologies Europe BV 
(Paisley, United Kingdom); Annexin V–fluorescein isothiocyanate (FITC) and 7-
aminoactinomycin D (7AAD) were purchased from Becton Dickinson Biosciences 
Pharmingen (San Diego, CA).  
 
Cell lines and culture conditions 
Seven different hematological cancer cell lines were herein evaluated. Cell lines were 
purchased from DSMZ (German Collection of Microorganisms and Cell Cultures, 
Braunschweig, Germany) or ATCC (Manassas,VA) and include: Jurkat and Molt-4 (T-acute 
lymphoblasic leukemia [T-ALL]); ML-2, MV4-11, and NOMO-1 (acute myeloid leukemia 
[AML]); Ramos (Burkitt’ lymphoma [BL]); and RPMI8226 (Multiple myeloma).  
Primary cells from 6 consenting patients were also analyzed. Study protocols were approved 
by the ethics committee at the University of Lausanne, and informed consent was obtained in 
accordance with the Declaration of Helsinki. Primary cells were collected from peripheral 
blood (purity > 90%) from patients with AML (n =1); and B-chronic lymphocytic leukemia 
(n=5, CLL). 
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All cells were cultured in RPMI (Gibco, Paisley, United Kingdom) supplemented with 10% 
heat inactivated fetal calf serum (FCS; Gibco) and 1% penicillin/streptomycin at 37°C 
(Bioconcept, Allschwil, Switzerland) in a humidified atmosphere of 95% air and 5% CO2. 
 
Flow cytometer analyses 
Various cellular effects induced byAPO866 on hematopoietic malignant cells were evaluated 
using a Beckman Coulter Cytomics FC500 flow cytometer and included following functional 
cell parameters: cell death, reactive oxygen species production, mitochondrial membrane 
potential, and caspase activation status. 
 
Cell death analysis 
APO866-induced cell death was determined using annexin-V and 7-aminoactinomycin D (7-
AAD) stainings as described by the manufacturer and analyzed using a flow cytometer. Dead 
cells were identified as annexin V+ and/or 7AAD +.  
 
Assessment of mitochondrial membrane potential 
Mitochondrial membrane potential (MMP) was determined using a flow cytometer after cell 
staining with either JC-1 or TMRE. JC-1 and TMRE are cell permeants, fluorescent dyes that 
readily accumulates in active mitochondria due to their relative negative charge. JC-1 
accumulates in the mitochondria, showing green fluorescence at a low mitochondrial 
membrane potential (MMP) and forming red fluorescent J-aggregates at higher membrane 
potential. Drop-in mitochondrial membrane potential is indicated by a decrease in the ratio of 
the red signal to the green signal. TMRE is a red-orange dye that readily accumulates in 
active mitochondria. Depolarized or inactive mitochondria have decreased membrane 
potential and fail to sequester TMRE. Briefly, cells were cultured in the presence or absence 
8 
 
of APO866 for 24 to 96 hours. Cells were centrifuged, resuspended in phosphate-buffered 
saline (PBS) containing 5 µM JC-1 or 50 nM TMRE, and were then incubated at 37°C for 15 
minutes in the dark. The cells were washed twice with pre-warmed PBS, and immediately 
analyzed using flow cytometry. 
 
Detection of cellular and mitochondrial reactive oxygen species (ROS) 
Intracellular levels of cytosolic and mitochondrial superoxide as well as hydrogen peroxide 
production were determined in APO866- and control- treated hematological malignant cells 
by flow cytometer using live-cell permeant specific fluorogenic probes, dihydroethidium 
(DHE), MitoSox, and DCFH-DA, respectively. DHE is oxidized to red fluorescent ethidium 
by cytosolic superoxide and MitoSox is selectively targeted to mitochondria, once in the 
mitochondria, it is oxidized by superoxide and exhibits red fluorescence. Whilst, DCFH-DA 
is cleaved by esterase to yield DCFH, a polar non-fluorescent product, but in presence of 
hydrogen peroxide the latter is oxidized to green fluorescent product, dichlorofluorescent 
(DCF). For cell staining, cells were centrifuged and the pellets were resuspended in PBS with 
a final concentration of 5 µM for each probe. The mixture was incubated in dark at 37°C for 
15 min. Then, the cell suspension was analyzed using a flow cytometer within 20 min. 
 
Lentiviral vectors and virus production 
Recombinant lentiviruses delivering anti-ATG shRNAs specific for human genes from TRC 
(the RNAi consortium) library in pLKO lentiviral vectors were used as follows: 
TRCN0000099431 for ATG5 (GenBankTM NM_004849), TRCN0000033552 for Beclin1 
(GenBankTM NM_003766), and TRCN0000007584 for ATG7 (GenBankTM NM_006395) 
(Openbiosystems). Self-inactivating lentiviral vectors were produced by cotransfecting 293T 
cells with the lentivirus expression plasmid and packaging plasmids using the calcium 
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phosphate method. Infectious lentiviruses were harvested at 48h posttransfection, the 
supernatant was collected, filtered, concentrated by ultracentrifugation, re-suspended in 1% 
bovine serum albumin in PBS and then stored at -80°C until use as described previously 
(Perrin et al., 2007). Viral particle content was assayed for the p24 core antigen by using the 
p24 antigen enzyme-linked immunosorbent assay (RETROtek, Gentaur, Paris, France) 
according to the manufacturer’s instructions. 
 
Infection and generation of stable knockdown cell lines 
To establish Jurkat or Ramos cell lines stably expressing a specific shRNA against ATGs, 6 × 
106 Jurkat or Ramos cells were seeded in T25 cell culture flask and transduced with 50 ng of 
p24/ml culture medium for each vector. In parallel, Jurkat or Ramos cells were transduced 
with a lentiviral vector encoding a scramble shRNA (shRNAsc) as an infection control. After 
48 h, the transduced cells were selected by adding 10μg/ml Puromycin (Invitrogen) for three 
days.  
 
Immunoblotting 
Protein samples were harvested in lysis buffer  containing 20 mmol/L HEPES, pH 7.4, 10 
mmol/L NaCl, 3 mmol/L MgCl2, 2.5 mmol/L EGTA, 0.1 mmol/L dithiothreitol, 50 mmol/L 
NaF, 1 mmol/L Na3VO4 or for LC3 expression analysis in  a Tris–HCl buffer, pH 7.4, 
containing 150 mM NaCl, 5 mM EDTA, 1% triton X-100, 2mM sodium orthovanadate, 
0.5mM phenylmethylsulphonyl fluoride, 0.05% aprotinin (w/v), and 1mM dithiotreitol. A 
protease inhibitor cocktail (Roche, 11873580001) was added. Lysates were sonicated and 
protein concentration was determined using a Bradford assay. Proteins (25–40 μg) were 
separated by SDS-PAGE on a 8, 10 or 14% polyacrylamide gel, and analyzed by 
immunoblotting. The following primary antibodies were used for protein immunodetection: 
10 
 
anti-APG7 (sc-33211, 1/1,000) rabbit polyclonal, anti-Beclin 1 (sc-11427, 1/1,000) and anti-
α-actine (MAB1501, 1/1,000) mouse monoclonal antibodies from Millipore, anti-Beclin1 (sc-
11427, 1/1000) from Santa Cruz Biotechnology; anti-LC3 (NB100-2220, 1/1,000) rabbit 
polyclonal antibody from Novus Biologicals; anti-catalase (#AF3398, 1/2000) goat polyclonal 
antibody from R&D systems, anti-active caspase-3 (#9661, 1/1,000) rabbit polyclonal 
antibodies from Cell Signaling Technology; anti p62/SQSTM1 (P0067, 1/1,000) rabbit 
polyclonal antibody from Sigma-Aldrich and anti-fodrin (#FG6090, 1/3,000) mouse 
monoclonal antibody from Biomol (Enzo Life Sciences). After incubation with primary 
antibody, the following secondary antibodies were applied: polyclonal goat anti-mouse or 
goat anti-rabbit IgG conjugated with IRDye 680 (LI-COR, B70920-02) or IRDye 800 (LI-
COR, 926-32210). Protein bands were visualized using the Odyssey Infrared Imaging System 
(LI-COR). Odyssey v1.2 software (LI-COR) was used for densitometric analysis. OD values 
were normalized according to Ponceau staining as loading control and expressed as a 
percentage of values obtained for control non-treated cells (non-infected or infected with 
control vector transducing the scramble shRNA) (100%).  
 
Immunocytochemistry and quantification of LC3-positive dots 
Jurkat cells cultured in 6 wells plate were centrifuged, fixed with 4% paraformaldehyde in 
PBS (pH 7.4) for 20 min on ice and then plated on poly-L-lysine coated glass slides. Jurkat 
cells were first incubated for blocking and permeabilization in PBS with 10% donkey serum 
and 0.1% Triton X-100 for 30min. Then, cells were incubated with the anti-LC3 rabbit 
polyclonal antibody (Abcam, ab48394, 1/100) diluted in 1.5% of donkey serum in PBS 
overnight at 4°C. Alexa Fluor 488 donkey-anti-rabbit (Invitrogen, A21206) or Alexa Fluor 
594 donkey-anti-rabbit (Invitrogen) secondary antibodies, diluted in PBS with 1% of donkey 
serum (1/200), were applied for 2 h at room temperature. After several washes in PBS, 
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Hoechst staining was done to reveal cell nuclei and slides were mounted with FluoroSave 
(Calbiochem, 345-789-20). Confocal images of immunocytochemistry against LC3 were 
acquired using a Zeiss LSM 710 confocal laser scanning microscope and images were then 
processed by with Adobe Photoshop 5.0. LC3-positive dots were analyzed using ImageJ 
software and expressed as a number of LC3-positive dots per cell per μm2.  
 
Quantitative Real-Time RT-PCR 
Total RNA was extracted using RNeasy Mini kit (Qiagen). Eluted RNA were analyzed 
(quantity and quality) using Agilent RNA 6000 Nano kit (Agilent Technologies). RNA was 
reverse transcribed to cDNA with the High Capacity cDNA Reverse Transcription kit 
(Applied Biosystem). Then, real-time quantitative PCR was performed with the MyiQ Single 
Color real-Time PCR detection system using iQ SyBR Green Supermix (Biorad) as described 
by Berta et al. 2008.  The following primers were used for human Atg5: forward 5’-
CCTTGGAACATCACAGTACAT-3’, reverse 5’- CATCTTCAGGATCAATAGCAG-3’; 
human GAPDH: forward 5’-CCCCCAATGTATCCGTTGTG-3’, reverse 5’-
TAGCCCAGGATGCCCTTTAGT-3’. 
 
Statistical Analysis  
All assays were performed in triplicate and expressed as the mean and standard deviation 
(SD). All pairewise comparisons were analyzed by Tukey-Kramer Multiple comparisons Test 
or by one-way ANOVA followed by Student’s t-test (2-tailed, 2-sample and unequal 
variance). GraphPad Prism version 6.00 (GraphPad Software, San Diego, CA) was used for 
statistical analysis. P values < .05 were considered statistically significant. 
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Results 
APO866 enhances autophagy in hematological malignant cells  
It is well known that APO866 triggers cell death in different types of malignant cells through 
NAD and ATP depletion. Several studies suggested various modes of cell death mechanisms 
induced by APO866, including apoptotic [2] [17-19] and autophagic [10, 16, 20] pathways. 
Although, the role of autophagy in cell death is under debate, evidences of autophagy-
mediated cell death in treated-cancer cells are now being revealed [21-24]. A recently 
published study, clearly showed that APO866 exerts its anti-tumor activities in multiple 
myeloma cells, not through apoptosis, but rather induction of autophagy-associated cell death 
via transcriptional-dependent (transcription factor EB, TFEB) and –independent (PI3K-
mTORC1) pathways [16, 25]. Multiple myeloma is a blood cancer characterized by the 
proliferation of plasma cells in the bone marrow. However, most of prior reports suggested 
that APO866 triggered apoptosis in various malignant cells [2, 17, 19, 26]. The contribution 
of apoptosis and autophagy in APO866-induced cell death seems to be cell dependent. We 
then examined whether APO866-induced cell death in leukemia/lymphoma cells is dependent 
on autophagic or apoptotic pathway. To provide evidence for autophagy induction in 
APO866-treated hematopoietic malignant cells, Jurkat cells were treated with or without 
APO866 and autophagic activity was determined by measuring (i) conversion of the 
cytoplasmic form of LC3 (LC3-I, 18KDa) to the preautophagosomal and autophagosomal 
membrane-bounded form of LC3 (LC3-II, 16KDa) by western blot, (ii) formation of LC3-
positive vesicles by LC3 immunolabelling using confocal microscopy and (iii) degradation of 
protein p62, a protein selectively degraded by autophagy [27-29]. In a first time, APO866 
induced a decrease in LC3-II level 24h after drug application. However this reduction was 
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followed by a significant increase in LC3-II suggesting a transitory activation of autophagy 
around 48h (Fig. 1A). This result was confirmed by the increase in LC3-positive dots in 
Jurkat cells treated with APO866 for 48h compared to control conditions, indicating an 
increase in autophagosome formation after APO866 treatment (Fig. 1B). To clarify whether 
increased autophagosome presence was due to enhanced autophagy flux or to reduced 
degradation of autophagosomes by defective lysosomal activity in APO866-treated Jurkat 
cells, we examined: (i) the expression level of p62 and (ii) monitored LC3-II conversion in 
presence of an inhibitor of autophagosome-lysosome fusion, chloroquine (CQ). Western blot 
analyses showed a decrease in p62 expression levels (Fig. 1C) and CQ treatment markedly 
increased LC3-II expression levels in APO866 treated-cells (Fig. 1D). These results 
demonstrate an increase of autophagic flux in Jurkat cells (enhanced autophagosome 
formation and active lysosomal degradation). Collectively, these findings support induction of 
autophagy in hematopoietic malignant cells after treatment with APO866.  
 
APO866 induces caspase-dependent apoptosis in hematological malignant cells 
This observation led us to examine whether apoptosis is also involved in the anti-leukemia 
effects of APO866. To this end, a time course analysis of caspase activation, a hallmark of 
apoptosis was evaluated in APO866-treated Jurkat cells. The caspases, a family of cysteine 
proteases, are subdivised into two groups: (a) initiator caspases, such caspase-8 and -9 [30], 
and (b) executioner caspases, such as caspase-3, -6, and -7 [31]. Western blot assay showed a 
steady increase of cleaved caspase-3 triggered by APO866 treatment in time dependent 
manner, and reaching a maximum at 72h (Fig. 2A). This observation suggests the 
involvement of caspase-dependent apoptotic pathway in anti-leukemic effects of APO866. To 
validate this finding, we then assessed activation of various caspases including caspase-8, -9, 
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and -3, on Jurkat cells treated for 72h with 10nM APO688 using the specific CaspGLOW™ 
Red Active for each caspase and flow cytometry. The caspGLOw assays offers a convenient 
way for measuring activated caspases in living cells. The assay uses a specific inhibitor for 
each caspase conjugated to sulfo-rhodamine as fluorescent marker which is cell permeable, 
non-toxic and irreversibly binds in specific manner to activated caspase in apoptotic cells. The 
red fluorescence label allows for direct detection of activated caspase in apoptotic cells by 
flow cytometry. APO866 treatment tremendously increases capsase-8, -9, and -3 activities in 
Jurkat cells (Fig. 2B), indicating that caspase-dependent apoptosis is involved in anti-
leukemia effects of APO866. To confirm whether the apoptosis induced by APO866 is not 
only restricted to Jurkat cells, hematopoietic cancer cells from 2 additional cell lines (ML2: 
acute myeloid leukemia M4; Ramos: Burkitt lymphoma) from different hematological 
malignancies were incubated with APO866 for 72 hours, and caspase activities detected as 
mentioned above. APO866 also elicited a high level of caspases activity in Ramos and ML2 
cells (Supplementary Fig. S1), confirming the involvement of apoptosis in the antitumor 
activities exerted by APO866 in various hematopoietic tumor cells. Unlike results reported for 
multiple myeloma cells [16], these results indicate that APO866 can induce both autophagy 
and apoptosis in human leukemia/lymphoma cells. 
 
Beclin1-independent autophagy is required for anti-leukemia/lymphoma effects of APO866 
Induction of autophagy has been proven to be either a survival-promoting [32] or a pro-death 
pathway depending on the stress conditions even if its exact implication in cell death remains 
controversial [13, 33]. In our previous study delineating mechanisms involved in APO866-
induced cell death in hematological malignancies, the implication of autophagy in this process 
was not clearly demonstrated but only suggested by the protective effect of autophagy 
pharmacological inhibitors [3]. In fact, we showed that PI3K inhibitors (3-methyladenine, 
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wortmanin, and LY294002) were capable of attenuating APO866-induced cell death in 
hematological malignancies, suggesting a contribution of autophagy in mediating cell death. 
However, PI3K inhibitors may affect both class I and III PI3K, which are implicated in 
various biological pathways. To provide strong evidences of specific implication of 
autophagy in APO866-induced cell death, autophagy was inhibited using lentiviral mediated 
transduction of shRNAs targeting Atg5, Atg7 and Beclin1 whose expressions are required to 
form autophagosomes. To provide evidences that autophagy-mediated cell death was not cell-
type dependent, the cytotoxic effect of APO866 was investigated in two selected (Jurkat and 
Ramos) lines from different hematological malignancies. If autophagy is involved in 
APO866-induced cell death, silencing Atg5, Atg7 or beclin1 will provide protection against 
APO866 treatment. Decreased beclin1, Atg5, and Atg7 expressions in transduced-Jurkat (Fig. 
3A-C) and Ramos (Supplementary Fig. 2A-C) cells were confirmed by either Western blot or 
RT-PCR. In addition, lentiviral vectors delivering shRNA against beclin1, Atg5 and Atg7 
decreased LC3-II  accumulation produced after 6h in presence of CQ in Jurkat and Ramos 
cells (Fig. 3D and Supplementary Fig. 2D ), validating the KD effect of each Atg by showing 
that autophagosome formation is reduced in these transduced malignant cells. Importantly, 
downregulation of ATG5 and ATG7, but not Beclin1 expression abrogated APO866-induced 
cell death in Jurkat and Ramos cells (Fig. 5A and Supplementary Fig. 3A) and this protection 
could still be observed 10 days after drug treatment (Fig. 5B and Supplementary Fig. 3B). 
These results clearly indicate that autophagy is a key player in APO866-induced cell death in 
Leukemia/lymphoma cells.  
Since caspase activation was detected in APO866-treated leukemia/lymphoma cells, we next 
examined whether APO866-induced cell death was also caspase-dependent. To this end, 
Jurkat, Ramos, and ML2 were treated with APO866 at different time points, and in presence 
or absence of a broad caspase inhibitor, z-VAD. Our results revealed that caspase inhibition 
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delayed but not prevented APO866-induced cell death (Fig. 6A and Supplementary Fig. 4), 
which suggests that caspases inhibition is not effective to prevent APO866-induced 
cytotoxicity. Moreover when caspase-3 activation was assessed by Western blot in Jurkat 
cells that are knockdown for Atg5 and Atg7. Cleavage of caspase-3 was fully prevented 72h 
after APO866 treatment compared to control vector infected and shRNA Beclin1 transduced 
cells (Fig. 6B and Supplementary Fig. 4B). This result suggests that autophagy induction acts 
upstream of caspase-3 and may contribute to its activation.  
Taken together, these results strongly suggest that APO866 induces cell death (i) highly 
dependent on autophagy, (ii) with activation of caspases which (iii) is regulated by autophagy. 
 
 
APO866 induces reactive oxygen species generation through autophagy-dependent catalase 
degradation 
We and others demonstrated that APO866 is a highly potent NAD depleting agents in various 
malignant cells [2, 3, 11, 16, 17, 20]. NAD(P)H/NAD(P)+ cell contents play a crucial role in 
numerous redox reactions. Cellular redox status is one of the main mechanisms involved in 
control and regulation of cell death pathways, including apoptotic, autophagic and necrotic 
processes. Depleting NAD is expecting to induce perturbation of NAD(P)H/NAD(P)+ ratio 
which will result in production of high levels of reactive oxygen species (ROS) that would 
lead to cell death. We then hypothesized that NAD depletion induced by APO866 in 
hematological malignant cells would result in increased ROS production that would lead to 
cell damage and finally to cell death.  To test this issue, cytosolic and mitochondrial 
superoxide productions as well as intracellular hydrogen peroxide were monitored in various 
hematological malignant cells treated with APO866 using DHE and Mitosox as well as 
DCFH-DA probe respectively. As expected, APO866 caused an increase level of both 
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cytosolic and mitochondrial ROS in all treated hematopoietic malignant cells (Fig. 7A and 
Supplementary Fig. 5A). As excessive ROS generation leads to mitochondrial damages, these 
findings are consistent with our previous study that reported the mitochondria depolarization 
in APO866-treated leukemia/lymphoma cells [3]. ROS accumulation may be caused by either 
an increase in ROS production or decreased ROS degradation. To explain the burst of ROS 
production in APO866-treated leukemia/lymphoma cells, we then investigated whether 
catalase, one of the key enzymatic ROS scavengers, was degraded in hematopoietic malignant 
cells from different hematological malignancies in presence of APO866. Western blot 
analysis demonstrated a decrease in catalase expression in all analyzed malignant cell lines in 
time-dependent manner (Fig. 7B and Supplementary Fig. 5B) suggesting a involvement of 
catalase degradation in ROS production. 
 
Autophagy acts upstream of ROS generation and mitochondrial depolarization in APO866-
treated malignant cells 
It has been shown that autophagy can be in some cases regulated by ROS (Chen et al., 2009, 
Scherz-Shouval et al., 2007; Szumiel, 2010) and in other cases be involved in ROS 
production (Kubota et al, 2010). To determine whether ROS accumulation in APO866-treated 
hematopoietic tumor cells is upstream or downstream of autophagy induction, we investigated 
the effect of ATG5 and ATG7 downregulation on ROS production. If ROS is acting upstream 
of autophagy induction, inhibition of autophagy with genetic approaches will have no effect 
on ROS production. Otherwise, autophagy inhibition will decrease or prevent ROS. To 
determine the role played by autophagy in APO866-induced ROS generation, shRNA 
transduced Jurkat and Ramos cells were exposed to APO866 for 72h and intracellular ROS 
production was measured using Mitosox, DCFH-DA and flow cytometer. Our data showed 
that downregulation of ATG5 and ATG7 strongly reduced the APO866-induced ROS 
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production (Fig. 8A-B and Supplementary Fig. 6A-B) compared to control vector and shRNA 
Beclin1 transduced or wt cells (Fig. 7A). This argues for autophagy induction upstream of 
ROS production.  
 
Autophagy degrades selectively catalase in APO866-treated malignant cells 
It has been reported that catalase could be a selective substrate of autophagy in condition of 
autophagy-mediated cell death [34]. Catalase degradation in APO866-treated hematological 
malignant cells could be then a way for autophagy to regulate ROS production. To test this 
hypothesis, Jurkat cells downregulated for Beclin1, ATG5 and ATG7 were incubated with or 
without APO866 for 72 hours and expression level of catalase was determined by western 
blot assay. Inhibition of autophagy by transduction of shRNA Atg5 and Atg7 totally 
abrogated catalase depletion on the contrary of transduction of shRNA Beclin1 and control 
vector (Fig. 8C and Supplementary Fig. 6C). Consequently, inhibition of beclin1-independent 
autophagy also prevented the mitochondrial depolarization induced by APO866 treatment 
(Fig. 8D Supplementary Fig. 6D). Altogether, these data strongly suggest that APO866-
induced autophagy is involved in catalase degradation and subsequent excessive ROS 
production which leads to loss of mitochondrial membrane potential and ultimately to cell 
death. 
 
Exogenous addition of catalase abrogates the anti-leukemic/lymphoma effects of APO866 
According to our data catalase appears to play a pivotal role in APO86-induced cell death in 
hematopoietic tumor cells. To provide evidence of involvement of catalase degradation in 
APO866-induced cell death, cells from lines and primary cells from patients diagnosed with 
various hematological malignancies were treated with or without APO866 in presence or 
absence of exogenous addition of catalase and cell death was monitored using annexin-V/7-
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aminoactinomycin-D (7-AAD) and flow cytometer. As expected, extracellular addition of 
catalase, completely blocked APO866-induced cell death in all analyzed tumor cells, 
independently of hematological malignancies (Fig. 9), highlighting its essential role in 
APO866-antitumor activities. Importantly, the protective effects of catalase were observed 
over a week after APO866 treatment (Fig. 9B). This finding confirms that catalase play a 
major role in APO866-induced cell death. 
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Discussion 
In the present study, we show that treatment of leukemia/lymphoma cells with APO866 
induces both autophagy and apoptosis, and that suppression of autophagy prevents APO866-
induced caspase activation in hematopoietic malignant cells. This suggests a crosstalk 
between autophagy and apoptosis. 
Apoptosis was revealed by observing increases in activation of caspase-8, -9, and -3 using 
flow cytometer and accumulation of cleaved caspase-3 fragment in APO866-treated 
malignant cells. Our data further reveals that pan-caspase inhibitor could not prevent, but only 
delay APO866-induced cell death, suggesting that both caspase-dependent and -independent 
cell death modes are involved. This confirms previous studies evidencing that apoptosis is a 
mechanism acting in APO866-induced cell death [2, 4, 17, 19], but tempers its strong 
association in hematological cancers studied here. 
We confirm here the involvement of autophagy, and indeed found that it plays an essential 
role, in such death. Evidences of autophagy induction in leukemia/lymphoma cells treated 
with APO866 were provided by (i) by western blot assays showing an accumulation of LC3-II 
and degradation of p62; (ii) immunobloting through increased formation of LC3 punctuas, 
and (iii) inhibition of autophagic markers in hematopoietic malignant cells knockdown in atg-
5 and -7, but not beclin. These latter inhibitions completely block APO866-induced cell death 
in different hematopoietic malignant cells, which provide the proof of direct implication of 
this autophagy loop in APO866- induced in leukemia/lymphoma cell death. In the last decade, 
autophagy has been extensively studied (refs…). In most studies, autophagy is functioning as 
survival mechanism under stress conditions (refs…). Its role in cell death is not well 
established. In efforts to elucidate molecular mechanisms by which APO866 triggers 
autophagy-associated cell death in leukemia/lymphoma cells, our results demonstrate that 
APO866 treatment in various hematopoietic malignant cells increases autophagic activities 
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which results in catalase degradation. Thus, depletion of catalase led to ROS (cytosolic and 
mitochondrial superoxide as well as intracellular hydrogen peroxide) accumulation and finally 
to cell death. To delineate the importance of catalase depletion in APO866, we show that 
exogenous addition of catalase totally blocked the APO866 killing effects in various 
hematological malignant cells. These findings provide for the first time the crucial role of 
antioxidants (catalase) in autophagy-associated cell death in APO866-treated hematopoietic 
malignant. However, based on our results, we cannot rule out the implication of other 
antioxidant enzymes in this process. Indeed, there are other antioxidants playing the same role 
as catalase in cell detoxification, i.e., glutathione peroxidase (GPx), and peroxiredoxin III 
(PrxIII). All these enzymes convert H2O2 to H2O (refs…). Additionally, extracellular 
addition of catalase has been reported to lower superoxide anion and by this way masking the 
effects of SOD depletion [35, 36]. Further experiments are warranted to explore the effects of 
APO866 treatment on all antioxidant enzymes in tumor cells.  
Our findings are consistent with previous studies that showed the implication of autophagy in 
cell (including myeloma cell) death ([10, 16, 20]. refs…), extend it to leukemia/lymphoma 
cells, and reveal that autophagy is essential for observing APO866-induced caspase activation 
in hematopoietic malignant cells. Autophagy may control apoptosis in APO866-treated 
leukemia/lymphoma cells through ROS production. We provide evidences that APO866 
triggers a tremendous increase of ROS production via antioxidant depletion. High level of 
ROS production is known to be deleterious for cell health, since it oxidizes proteins, lipids, 
and cell organelles, including mitochondria ending with cell death. This explains the 
depolarization of mitochondria observed in APO866-treated hematopoietic malignant cells. 
Furthermore, accumulation of ROS in mitochondria is known to impair ATP production, 
induce membrane permeabilization, and lead to apoptosis. Consequently, inhibition of 
autophagy will preserve the cellular antioxidant contents, which will block APO866-induced 
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ROS production, and thus avoiding apoptosis. Importantly, unlike previous studies published 
elsewhere, autophagy induced by APO866 treatment in leukemia/lymphoma is upstream of 
ROS production. Here, we did not address how APO866 initiates autophagy in 
leukemia/lymphoma cells; it could be through inhibition of mTORC1 and via TFEB 
pathways, as it was shown in multiple myeloma cells [25]. Question whether this issue is 
similar in leukemia/lymphoma cells needs to be clarified.  
In conclusion, we demonstrate induction of autophagy and apoptosis upon APO866 treatment 
in leukemia/lymphoma cells. Apoptosis was induced by both caspase-dependent and -
independent pathways and was under control of autophagy. Autophagy-associated cell death 
was likely induced in non-canonical pathways; i.e., through atg5/atg7-dependent pathways. 
These findings open new way of modulating autophagic machinery as approach of enhancing 
the antitumor activities of APO866. Efforts to unravel the molecular mechanisms underlying 
APO866-induced cytotoxicities in various tumor cells are expected to greatly improve our 
understanding of mechanisms that take part in control of APO866-induced cell death. This 
may provide a stepping stone towards future development of novel anticancer therapy 
approaches. 
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Legends 
Figure 1. APO866 induces autophagy in Jurkat cells. (A) Western blot analysis and 
corresponding quantification of LC3-II form in untreated control cells (ct) and treated 
Jurkat cells. Malignant cells were incubated with APO866 (10 nM) at different time 
points. The LC3-II protein was detected by western blot using a specific polyclonal 
antibody. Relative intensity of LC3-II was calculated by normalizing the LC3-II intensity 
to actin using ImageJ Version 1.46 analysis software. Data are mean ± SD, n ≥ 7. (B) 
Confocal images of Jurkat cells immunolabelled for LC3 (in red) and Hoechst-stained 
(nuclei) with quantification of the number of LC3-positive dots (autophagosomes) per 
cell per µm2 demonstrate that exposure to AP0866 for 48h. n=40. Bar = 10µm. 
Fluorescence was recorded using a Nikon E800 epifluorescence microscope equipped 
with a Coolsnap CF color camera (Nikon; 40x magnification). Quantification of LC3-
positive dots per cells per µm2. Data are mean ± SD; n= 40 cells per conditions. Bar = 
10µm. (C) Western blot analysis and corresponding quantification of p62 protein in 
untreated control cells (ct) and treated Jurkat cells. Cells were cultured as mentioned in 
(A) and p62 detected using specific polyclonal antibody. Data are mean ± SD, n ≥ 5. (D) 
Western blot analysis and corresponding quantification of LC3-II form in untreated 
control cells (ct) and treated Jurkat cells in presence of chloroquine, a lysosomal 
inhibitor. Jurkat cells were pre-treated with 25 CQ µM for 1 hour before APO866 
treatement for 72 hours. LC3-II was detected and quantified as mentioned above. Data 
are mean ± SD, n ≥ 5. **p<0.01; ***p<0.001. 
 
Figure 2. APO866 activates caspases in Jurkat cells. (A) Western blot and 
corresponding quantification of cleaved caspase-3 in utreated control cells (ct) or at 
different time points after APO866 (10nM) treatment.  Jurkat cells were incubated with 
APO866 (10 nM) at different time points. The 19 and 17kDa fragments of caspase-3 
(cleaved forms) were detected by western blot using a specific polyclonal antibody. 
Relative intensity of cleaved caspase-3 forms were similarly calculated as in Fig. 1A. 
Data are mean ± SD; ***p<0.001; n ≥ 5. (B) Detection of fluorescent activated caspases. 
Jurkat cells were treated with 10 nM APO866 for 72 hours and activated forms of 
caspase-3, -8, and -9 were detected using fluorescent probe specific for each caspase and 
flow cytometry. Data are representative of three independent experiments.   
 
Figure 3. Beclin1, Atg7 and Atg5 are efficiently downregulated in Jurkat cells. Jurkat 
cells were transduced with either control scrambled or lentiviral constructs expressing 
shRNA targeting Atg5, Atg7, and beclin1. 48 hours after transduction, cell lysates or 
mRNA were subjected to Western blot analysis or RT-PCR to monitor BECLIN (A), 
ATG7 (B) protein or Atg5 mRNA (C) expressions, respectively. (D) Western blot 
analysis and corresponding quantification of LC3-II form in untreated control Jurkat cells 
transduced with either control scrambled or lentiviral constructs expressing shRNA 
targeting Atg5, Atg7, and beclin1. Cells deficient in autophagy were cultured with CQ for 
6 hours and LC3-II protein expressions were assessed by Western blot and quantified as 
mentioned above. . Data are mean ± SD, n = 6. **p<0.01; ***p<0.001. 
 
Figure 4. Downregulation of Atg5 and Atg7 prevent APO866-induced autophagy in 
Jurkat cells. Western blot analysis and corresponding quantification of p62 protein in 
untreated (ct) or APO866-treated Jurkat cells knocked down for beclin 1, Atg5 and Atg7.  
Malignant cells were cultured in presence or absence of 10nM APO866 for 72 hours and 
cell lysates were subjected to Western blot analysis to assess p62 protein expression. Data 
are mean ± SD, n≥6.  *p<0.05, ***p<0.001. 
 
 
Figure 5. Autophagy is required for APO866-induced cell death. Cell death induced 
by APO866 on wild type and autophagy deficient Jurkat cells. Cell death was assessed by 
flow cytometry using annexin-V and 7AAD stainings after 72 hours (A) and 240 hours 
(B) treatments. The percentage of early apoptotic cells (annexin V+7AAD-) are shown as 
white columns and that of late apoptotic cells (annexin V+7AAD+) are shown as solid 
black columns. Data are mean ± SD, n≥3. ***p<0.001. 
 
Figure 6. Autophagy contributes to APO866-induced caspase-3 activation in Jurkat 
cells. (A) Time course analysis of cell death induced by APO866 on Jurkat cells in 
presence of pan-caspase inhibitor, zVAD-fmk Wild type Jurakt cells were exposed to 10 
nM APO866 in presence of 100 µM zVAD-fmk and cell death was monitored as 
mentioned in Fig. 5. Data are mean ± SD, n=3.  **p<0.01. (B) Western blot analyses and 
corresponding quantifications of cleaved caspase-3 in scrambled (sc) and autophagy 
deficient Jurkat cells. Cells were exposed to 10 nM APO866 and cleaved caspase-3 forms 
were detected and quantified as mentioned above. Data are mean ± SD, n≥10.  *p<0.05, 
**p<0.01; ***p<0.001. 
 
 
Figure 7. APO866 induces ROS generation and catalase degradation in Jurkat cells. 
(A) Detection of ROS production in Jurkat cells treated with APO866. Cells were 
incubated without or with 10 nM APO866 and cytosolic, mitochondrial superoxide and 
hydrogen peroxide were detected by flow cytometry using DHE, mitosox,and DCFDA 
fluorescent probe, respectively. Data are mean ± SD, n=3; ***p<0.001. (B) Western blot 
analysis and corresponding quantifications of catalase expression in wild-type Jurkat 
cells. Cells were exposed to 10 nM APO866 and catalase expression was detected and 
quantified in time dependent manner as mentioned above. . Data are mean ± SD, n≥9.  
*p<0.05, **p<0.01; ***p<0.001. 
 
Figure 8. Autophagy is involved in APO866-induced ROS generation and catalase 
degradation in Jurkat cells. Detection of ROS production in wild type and autophagy 
deficient Jurkat cells exposed to APO866. Cells were incubated without or with 10 nM 
APO866 and mitochondrial superoxide (A) and hydrogen peroxide (B) were detected as 
mentioned above. Data are derived from at least 3 independent experiments. (C) Western 
blot analysis and corresponding quantifications of catalase expression in wild type and 
autophagy deficient Jurkat cells exposed to APO866. Cells were exposed to 10 nM 
APO866 for 72 hours and catalase expression was detected and quantified as mentioned 
above. Data are mean ± SD, n≥8.  ***p<0.001.  (D) Detection of Mitochondrial potential 
in wild type and autophagy deficient Jurkat cells exposed to APO866. Cells were 
incubated without or with 10 nM APO866 and the mitochondrial potential was measured 
using JC-1 and flow cytometry staining red versus green fluorescence as described in 
“Methods.” Data are derived from at least 3 independent experiments. ***p<0.001. 
 
Figure 9. Extracellular addition of catalase prevents APO866-mediated cell death in 
various hematopoietic malignant cells. Cells were incubated with or without 500 (or 
1000) U catalase in presence or absence of 10 nM APO866. Cell death was assessed 96 
hours (A) and 168 hours (B) after drug exposure and as described above. Data are derived 
from at least 3 independent experiments. 
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